These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The old and new: PCCs, VIIa, and long-lasting clotting factors for hemophilia and other bleeding disorders. Ragni MV Hematology Am Soc Hematol Educ Program; 2013; 2013():44-51. PubMed ID: 24319161 [TBL] [Abstract][Full Text] [Related]
4. Lasting power of new clotting proteins. Powell JS Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):355-63. PubMed ID: 25696879 [TBL] [Abstract][Full Text] [Related]
5. Changing Paradigm of Hemophilia Management: Extended Half-Life Factor Concentrates and Gene Therapy. Kumar R; Dunn A; Carcao M Semin Thromb Hemost; 2016 Feb; 42(1):18-29. PubMed ID: 26771678 [TBL] [Abstract][Full Text] [Related]
6. The history of hemophilia. Franchini M; Mannucci PM Semin Thromb Hemost; 2014 Jul; 40(5):571-6. PubMed ID: 24911674 [TBL] [Abstract][Full Text] [Related]
7. Why should we care about quality of life in persons with haemophilia? Aledort L; Bullinger M; von Mackensen S; Wasserman J; Young NL; Globe D; Haemophilia; 2012 May; 18(3):e154-7. PubMed ID: 22356125 [TBL] [Abstract][Full Text] [Related]
8. Hemophilia: new protein therapeutics. Pipe SW Hematology Am Soc Hematol Educ Program; 2010; 2010():203-9. PubMed ID: 21239795 [TBL] [Abstract][Full Text] [Related]
9. Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Grosse SD; Chaugule SS; Hay JW Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):267-83. PubMed ID: 25585817 [TBL] [Abstract][Full Text] [Related]
10. The hope and reality of long-acting hemophilia products. Pipe SW Am J Hematol; 2012 May; 87 Suppl 1():S33-9. PubMed ID: 22389200 [TBL] [Abstract][Full Text] [Related]
12. Past, present and future of hemophilia: a narrative review. Franchini M; Mannucci PM Orphanet J Rare Dis; 2012 May; 7():24. PubMed ID: 22551339 [TBL] [Abstract][Full Text] [Related]
13. Toward optimal therapy for inhibitors in hemophilia. Kempton CL; Meeks SL Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):364-71. PubMed ID: 25696880 [TBL] [Abstract][Full Text] [Related]
14. Life expectancy in hemophilia outcome. Mejia-Carvajal C; Czapek EE; Valentino LA J Thromb Haemost; 2006 Mar; 4(3):507-9. PubMed ID: 16460431 [No Abstract] [Full Text] [Related]
15. The history of haemophilia - a short review. Schramm W Thromb Res; 2014 Nov; 134 Suppl 1():S4-9. PubMed ID: 24513149 [TBL] [Abstract][Full Text] [Related]
17. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Schaub RG Biochem Pharmacol; 2011 Jul; 82(2):91-8. PubMed ID: 21453683 [TBL] [Abstract][Full Text] [Related]
19. Modern haemophilia care. Berntorp E; Shapiro AD Lancet; 2012 Apr; 379(9824):1447-56. PubMed ID: 22456059 [TBL] [Abstract][Full Text] [Related]
20. Extended Half-Life Coagulation Factors: A New Era in the Management of Hemophilia Patients. Ar MC; Balkan C; Kavaklı K Turk J Haematol; 2019 Aug; 36(3):141-154. PubMed ID: 31088040 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]